Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Holding(s) in Company

13 Oct 2014 08:20

RNS Number : 0908U
Sareum Holdings PLC
13 October 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Sareum Holdings plc.

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

YA Global Master SPV, Ltd

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

October 1 2014

6. Date on which issuer notified:

October 10, 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

Cross 3% Threshold

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect x

Direct

Indirect

65,665,125

65,665,125

55,962,500

55,962,500

2.9

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

55,962,500

2.9%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Steven Goldstein

15. Contact telephone number:

201-985-8300

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

YA Global Master SPV, Ltd

Contact address

(registered office for legal entities)

 

1012 Springfield Ave., Mountainside, NJ 07092

Phone number & email

 

201-985-8300

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Steven S. Goldstein

Contact address

 

1012 Springfield Ave., Mountainside, NJ 07092

Phone number & email

 

201-985-8300 & sgoldstein@yorkvilleadvisors.com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMJBRTMBBBMAI
Date   Source Headline
1st May 20267:00 amRNSExercise of Warrants
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
12th Mar 20267:00 amRNSHalf-Year Report for Six Months Ended 31 Dec 2025
3rd Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSRestart of Phase 2-enabling toxicology programme
23rd Jan 20264:36 pmRNSForm 8.3 - Oxford Biomedica plc
9th Dec 20254:25 pmRNSResults of AGM
9th Dec 20257:00 amRNSAnnual General Meeting Statement
17th Nov 20257:00 amRNSNotice of AGM, Annual Report and Accounts
30th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Oct 20257:00 amRNSPreliminary Results for Year Ended 30 June 2025
10th Oct 20257:00 amRNSUpdate on toxicology study for SDC-1801
7th Oct 20257:00 amRNSNotice of Results and Investor Presentation
26th Sep 20253:12 pmRNSExercise of Warrants
18th Sep 202512:59 pmRNSExercise of Warrants
26th Aug 20257:00 amRNSExercise of Warrants
20th Aug 202510:01 amRNSExercise of Warrants
12th Aug 20257:00 amRNSSareum Collaboration with Receptor.AI
9th Jul 20257:00 amRNSExercise of Warrants
4th Jul 20257:00 amRNSAppointment of Sole Broker
29th May 20257:00 amRNSInitiation of Toxicology Studies for SDC-1801
28th Apr 20257:00 amRNSUpdate on TYK2/JAK1 and SRA737 Programmes
24th Apr 20257:00 amRNSExercise of Warrants
27th Mar 20257:00 amRNSDirector’s Dealing
25th Mar 20257:00 amRNSSareum Half-Year Report
20th Mar 20257:00 amRNSNotice of HY Results and Investor Presentation
13th Mar 20257:15 amRNSInstitutional Equity Fundraise
13th Mar 20257:08 amRNSSareum Acquires Licence for SRA737
31st Dec 20247:00 amRNSUpdate on SRA737
19th Dec 20244:07 pmRNSResults of AGM
19th Dec 20247:00 amRNSAGM Statement
18th Dec 20247:00 amRNSAppointment of Joint Broker
17th Dec 20249:14 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSAward of Share Options
27th Nov 20249:38 amRNSNotice of AGM, Annual Report and Accounts
29th Oct 20247:00 amRNSFinal Results for the Year Ended 30 June 2024
23rd Oct 20247:00 amRNSNotice of Final Results and Investor Presentation
21st Oct 20247:00 amRNSFurther Subscription to raise £1,000,000
11th Oct 20247:00 amRNSSubscription to raise £2,364,000
16th Sep 20247:00 amRNSPatent Allowance in China
2nd Sep 20247:00 amRNSUS patent allowance
10th Jul 20247:00 amRNSManagement Changes
1st Jul 20247:00 amRNSPositive Data from SDC-1801 Phase 1 Clinical Trial
30th May 20247:00 amRNSAppointment of Sole Broker
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares
4th Apr 20242:38 pmRNSCompletion of Equity Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.